Madrigal Faces Troubling Whistleblower Claims
Whistleblower Complaint Rocks Madrigal Let me tell you, today's chatter isn't for the faint-hearted investor. Madrigal Pharmaceuticals (NASDAQ: MDGL) is under scrutiny, and it's making waves. The gears started turning when their former Senior VP and Head of Clinical Development unloaded a bombshell: he reported dirt on Madrigal's safety and efficacy data for Rezdiffra,...
Continue Reading